165 related articles for article (PubMed ID: 10930366)
21. Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis.
Mallolas J; Esteve M; Rius E; Cabré E; Gassull MA
Gut; 2000 Jul; 47(1):74-8. PubMed ID: 10861267
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.
Seibold F; Weber P; Klein R; Berg PA; Wiedmann KH
Gut; 1992 May; 33(5):657-62. PubMed ID: 1612483
[TBL] [Abstract][Full Text] [Related]
23. Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis.
Hov JR; Boberg KM; Taraldsrud E; Vesterhus M; Boyadzhieva M; Solberg IC; Schrumpf E; Vatn MH; Lie BA; Molberg Ø; Karlsen TH
Liver Int; 2017 Mar; 37(3):458-465. PubMed ID: 27558072
[TBL] [Abstract][Full Text] [Related]
24. [Autoimmune hepatitis and overlap syndrome: diagnosis].
Berg PA; Klein R
Praxis (Bern 1994); 2002 Aug; 91(34):1339-46. PubMed ID: 12233264
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens?
Seibold F; Weber P; Schöning A; Mörk H; Goppel S; Scheurlen M
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1095-100. PubMed ID: 8944372
[TBL] [Abstract][Full Text] [Related]
26. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.
Rump JA; Schölmerich J; Gross V; Roth M; Helfesrieder R; Rautmann A; Lüdemann J; Gross WL; Peter HH
Immunobiology; 1990 Nov; 181(4-5):406-13. PubMed ID: 2099908
[TBL] [Abstract][Full Text] [Related]
27. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens.
Sugi K; Saitoh O; Matsuse R; Tabata K; Uchida K; Kojima K; Nakagawa K; Tanaka S; Teranishi T; Hirata I; Katsu K
Am J Gastroenterol; 1999 May; 94(5):1304-12. PubMed ID: 10235211
[TBL] [Abstract][Full Text] [Related]
28. Antineutrophil cytoplasmic antibody in patients with antinuclear antibody-positive chronic hepatitis C.
Ohira H; Tojo J; Shinzawa J; Suzuki T; Miyata M; Nishimaki T; Kasukawa R
Fukushima J Med Sci; 1998 Dec; 44(2):83-92. PubMed ID: 10091380
[TBL] [Abstract][Full Text] [Related]
29. Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis.
Bansi DS; Lo S; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):111-6. PubMed ID: 8723413
[TBL] [Abstract][Full Text] [Related]
30. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
[TBL] [Abstract][Full Text] [Related]
31. High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis.
Sobajima J; Ozaki S; Uesugi H; Osakada F; Inoue M; Fukuda Y; Shirakawa H; Yoshida M; Rokuhara A; Imai H; Kiyosawa K; Nakao K
Gut; 1999 Jun; 44(6):867-73. PubMed ID: 10323891
[TBL] [Abstract][Full Text] [Related]
32. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases.
Roozendaal C; Kallenberg CG
Hepatogastroenterology; 1999; 46(30):3034-40. PubMed ID: 10626156
[TBL] [Abstract][Full Text] [Related]
33. [Antibodies to neutrophilic granulocytes (p-ANCA): a further indication for a common origin of ulcerative colitis and primary sclerosing cholangitis?].
Jahn HU; Zeitz M
Z Gastroenterol; 1992 Jun; 30(6):441-2. PubMed ID: 1636280
[No Abstract] [Full Text] [Related]
34. Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis.
Ellerbroek PM; Oudkerk Pool M; Ridwan BU; Dolman KM; von Blomberg BM; von dem Borne AE; Meuwissen SG; Goldschmeding R
J Clin Pathol; 1994 Mar; 47(3):257-62. PubMed ID: 8163698
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases.
Roozendaal C; de Jong MA; van den Berg AP; van Wijk RT; Limburg PC; Kallenberg CG
J Hepatol; 2000 May; 32(5):734-41. PubMed ID: 10845659
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies to beta tubulin in autoimmune liver diseases-Relation to pANCA and clinical relevance.
Preuß B; Frank A; Terjung B; Spengler U; Berg C; Klein R
Clin Exp Immunol; 2024 Apr; 216(2):146-158. PubMed ID: 37823420
[TBL] [Abstract][Full Text] [Related]
37. Antineutrophil cytoplasmic auto-antibodies (ANCA) in autoimmune hepatitis and primary sclerosing cholangitis.
Deniziaut G; Ballot E; Johanet C
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):105-7. PubMed ID: 22998811
[No Abstract] [Full Text] [Related]
38. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates.
Mulder AH; Broekroelofs J; Horst G; Limburg PC; Nelis GF; Kallenberg CG
Clin Exp Immunol; 1994 Mar; 95(3):490-7. PubMed ID: 8137544
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis.
Seibold F; Slametschka D; Gregor M; Weber P
Gastroenterology; 1994 Aug; 107(2):532-6. PubMed ID: 8039629
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
